All Content Outsourced Pharma

  1. WuXiHigh 2.0 Delivers A 180 mg/mL Formula 3/26/2026

    This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

  2. Systematic Strategy To Reduce The Cost Of Goods Sold 3/26/2026

    Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

  3. WuXia293Stable: Express What CHO Can't 3/26/2026

    Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.

  4. Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing 3/26/2026

    See how modern tool enzymes enable cleaner, more consistent ADC conjugation, sharper analytics, and a smoother path from research to clinical development — practical guidance for manufacturing.

  5. Kindeva® Commemorates 70 Years Of The pMDI As Inventors Are Inducted Into The 'National Inventors Hall Of Fame' 3/26/2026
  6. Lifecore Biomedical Signs Two New Agreements With Existing U.S. Biopharmaceutical Customer 3/26/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.

  7. Neion Bio Emerges From Stealth With Multi-Product Biosimilar Partnership Leveraging Its Cutting-Edge Genetic Engineering Platform 3/26/2026

    Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced its emergence from stealth and the signing of its first co-development and supply agreement with a major global pharmaceutical company.

  8. SHINE And C-Ray Therapeutics Establish Strategic Partnership For Exclusive Distribution Of Non-Carrier-Added Lu-177 In Mainland China 3/26/2026

    SHINE Technologies, LLC today announced a supply agreement with C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, establishing C-Ray as SHINE's exclusive distribution partner for non-carrier-added lutetium-177 (n.c.a. Lu-177) across mainland China, excluding certain pre-existing SHINE partnerships.

  9. Navigating GMP Biosafety Challenges In ATMP Manufacturing 3/26/2026

    BioPhorum's survey findings reveal a wide variation in how biosafety is managed within GMP environments for viral-based ATMPs, underscoring the need for harmonized guidance.

  10. Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics 3/25/2026

    Clarity Pharmaceuticals (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics.